This study is in progress, not accepting new patients
ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at UCSF
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Alnylam Pharmaceuticals
- ID
- NCT03338816
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated